Highest-materiality recent filing
Elite Pharmaceuticals reports positive bioequivalence for undisclosed anticonvulsant generic drug
Pivotal BE study successful; generic product bioequivalent to branded anticonvulsant under fasting conditions.
Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available
ANDA submitted to FDA for generic version of an undisclosed anticoagulant drug product.
Elite Pharmaceuticals launches generic methadone tablets; addresses $22M market
Launched generic methadone HCl 5 mg and 10 mg tablets under Elite Laboratories label.
Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M
Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.
Elite Pharmaceuticals to release Q3 FY2026 results Feb 17, host call Feb 18
Q3 FY2026 financial results will be released on Tuesday, February 17, 2026.
Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)
Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.
Elite Pharmaceuticals Corrects Conference Call Date for Q2 Fiscal 2026 Results
Q2 FY2026 financial results (ended Sept 30, 2025) to be released on Friday, November 14, 2025.
Elite Pharmaceuticals receives FDA approval for generic Requip XL (ropinirole ER) tablets
FDA approved ANDA for generic Requip XL (Ropinirole Extended-Release Tablets USP) in 2,4,6,8,12 mg strengths.
Elite Pharma to release Q2 FY2026 results Nov 14; conference call Nov 17
Q2 FY2026 financial results (ended Sep 30, 2025) to be released on Friday, November 14, 2025.
Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%
Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.
Elite Pharmaceuticals announces Q1 FY2026 results release on Aug 14, conference call Aug 15
Financial results for Q1 FY2026 (ended June 30, 2025) to be released August 14, 2025.
Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)
Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.
Elite Pharmaceuticals to report FY2025 results June 30, host call July 1
FY2025 (ended March 31, 2025) financial results to be released June 30, 2025.
Positive pivotal bioequivalence results for an undisclosed generic anticoagulant; product is bioequivalent to brand.
Elite launches generic Percocet (oxycodone/acetaminophen) tablets in 3 strengths
Launched generic oxycodone HCl/acetaminophen tablets in 5/325, 7.5/325, and 10/325 mg strengths.
Elite Pharmaceuticals ships first product from new FDA-approved expanded campus
First lot of finished product shipped from new facility at 144 Ludlow Avenue, Northvale, NJ.
Elite Pharma Q3 fiscal 2025 revenue $14.4M (-8% YoY); operating profit $1.1M (-69%)
Consolidated revenue $14.4M for quarter ended Dec 31, 2024, down 8% from $15.6M in prior-year period.
Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD
Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.
Elite Pharmaceuticals launches generic Norco (hydrocodone/acetaminophen) tablets
Launched generic Norco (hydrocodone bitartrate/acetaminophen) in 2.5/325, 5/325, 7.5/325, and 10/325 mg strengths.
Elite Pharma gets FDA nod for generic Vyvanse; $4.3B market
Received FDA approval on November 15, 2024 for ANDA for generic Lisdexamfetamine Dimesylate (Vyvanse) in 7 strengths (10-70 mg capsules).
Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)
Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.
Israeli Ministry of Health approves Elite's generic Adderall; first shipment months away
Israeli Ministry of Health approved Elite's generic Adderall (mixed amphetamine salts) in 10mg, 20mg, 30mg tablets on Oct 7, 2024.
Elite Pharmaceuticals launches generic Tylenol with Codeine tablets across three strengths
Launched generic acetaminophen/codeine phosphate tablets in 300mg/15mg, 300mg/30mg, 300mg/60mg.
Elite Pharmaceuticals launches generic methotrexate sodium 2.5 mg tablets
Product launched for ALL, mycosis fungoides, non-Hodgkin's lymphoma, rheumatoid arthritis, severe psoriasis, pJIA.
Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%
Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.
Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)
Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.
Elite Pharmaceuticals acquires three ANDAs from Nostrum Laboratories for $900k
Acquired ANDAs for generic Norco (hydrocodone/APAP), Percocet (oxycodone/APAP), and Dolophine (methadone) from Nostrum.
Mazars USA resigned as auditor effective June 1, 2024, as substantially all partners/employees joined Forvis, LLP (renamed Forvis Mazars, LLP).
Elite Pharma receives FDA approval for generic Methotrexate; market $64.3M annual sales
FDA approved ANDA for generic Methotrexate Sodium 2.5 mg tablets on May 16, 2024.
Elite Pharma Q3 revenue up 68% to $15.5M; operating profit up 80% to $3.5M
Revenue $15.5M for Q3 FY2024 ended Dec 31, 2023, +68% YoY from $9.2M.
Elite Pharmaceuticals files ANDA for generic CNS stimulant; market $5.1B
ANDA accepted for review by FDA on Dec 21, 2023 for undisclosed generic CNS stimulant.
Elite Pharmaceuticals ships first order of generic Adderall XR to distributor Prasco
First shipment of generic Adderall XR (5-30 mg extended-release amphetamine capsules) to Prasco, LLC.
Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)
Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.
Elite Pharmaceuticals files ANDA for generic opiate analgesic with $720M market
Filed ANDA with FDA on August 17, 2023 for a generic opiate analgesic product.
Elite Pharmaceuticals reappoints Carter Ward as CFO effective Sept 5, 2023
Carter Ward reappointed CFO, secretary, treasurer; previously served from July 2009 to May 2021.
Elite Pharma Q1 revenue up 17% to $9.0M; net income up 267% to $1.1M
Revenue $9.0M (+16.9% YoY); operating profit $1.6M (+60% YoY).
Elite Pharmaceuticals dismisses Buchbinder, appoints Mazers as new auditor
Audit Committee approved appointment of Mazers USA LLP on July 11, 2023, effective same day.
Elite Pharma FY2023 revenue $34.2M (+5.9% YoY); operating profit down $1.4M
FY2023 revenues $34.2M, up 5.9% from prior year; net income $3.6M.
Elite Pharmaceuticals appoints Mark Pellegrino as CFO effective May 1, 2023
Mark Pellegrino appointed CFO, replacing Robert Chen, effective May 1, 2023.
Elite Pharmaceuticals files ANDA for generic antimetabolite; $42M market
Filed Abbreviated New Drug Application with FDA for an undisclosed generic antimetabolite drug.
On September 5, 2023 (the “Effective Date”), Carter J. Ward was appointed as the Company’s chief financial officer, secretary, and treasurer.
On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.
On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.
Max materiality 0.80 · Median 0.60 · Most common event other_material